The Jonathan Coleman Lab
Our lab is focused on understanding the mechanism of disease recurrence, response to therapies and disease progression of upper tract urothelial cancer, a rare but aggressive disease. To interrogate molecular diversity of the disease, we employ genomics, transcriptomics, metabolomics and tumor immune microenvironment profiling of patient samples as well as patient derived organoids and xenograft models generated in our lab.
Our laboratory has also been developing novel photodynamic therapies for local tumor ablation. The preclinical models are used in support of translational studies for ongoing clinical trials across multiple cancer types. Combination studies of photoablation with immunotherapies are an active area of investigation
Kim K, Hu W, Audenet F, Almassi N … Hakimi AA, Rosenberg JE, Iyer G, Vargas HA, Scaltriti M, Al-Ahmadie H, Solit DB, Coleman JA. Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nat Commun. 2020 Apr 24;11(1):1975. doi: 10.1038/s41467-020-15885-7.
Haedicke K, Agemy L, Omar M, Berezhnoi A, Roberts S, Longo-Machado C, Skubal M, Nagar K, Hsu HT, Kim K, Reiner T, Coleman J, Ntziachristos V, Scherz A, Grimm J. High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies. Nat Biomed Eng. 2020 Mar;4(3):286-297. doi: 10.1038/s41551-020-0527-8. Epub 2020 Mar 12.
Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, Brugarolas J, Chen YB, Linehan WM, Maher ER, Merino MJ, Offit K, Reuter VE, Shuch B, Coleman JA. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. Eur Urol. 2019 Dec;76(6):754-764. doi: 10.1016/j.eururo.2019.06.015. Epub 2019 Jul 18.
Wong NC, Alvim RG, Sjoberg DD, Shingarev R, Power NE, Spaliviero M, Murray KS, Benfante NE, Hakimi AA, Russo P, Coleman JA. Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. Eur Urol Focus. 2019 Nov;5(6):977-979. doi: 10.1016/j.euf.2019.04.003. Epub 2019 Apr 25. [PMID: ]
Lebdai S, Gigoux M, Alvim R, Somma A, Nagar K, Azzouzi AR, Cussenot O, Merghoub T, Wolchok JD, Scherz A, Kim K, Coleman J. Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. Oncoimmunology. 2019 Mar 28;8(6):e1581528. doi: 10.1080/2162402X.2019.1581528. eCollection 2019.
Jonathan Coleman, MD
- Jonathan Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of urologic malignancies. Ongoing work includes the development of local ablative therapies, their influence on the tumor microenvironment, and implications for therapy response.
- MD, Cornell University Medical College
- PhD, Biomedical Informatics (2014), Rutgers, The State University of New Jersey, NJ
- MS, Computer Science (1999), New Jersey Institute of Technology, NJ
- MS, Immunology (1995), College of Medicine, National Taiwan University, Taipei, Taiwan
- BS, Medical Technology (1993), Taipei Medical University, Taipei, Taiwan
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jonathan Coleman discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.